Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

GlaxoSmithKline: An update on SFO investigation

Jaclyn Jaeger | February 8, 2018

GlaxoSmithKline isn’t out of the weeds yet. The pharmaceutical company this week said the U.K. Serious Fraud Office has requested new information relating to an ongoing investigation, this time concerning third-party advisers engaged by the company.

The latest request relates to an ongoing inquiry that the SFO began in May 2014 into the group’s commercial operations in numerous countries, including China. “The SFO has requested information from the group on its commercial operations in these countries,” GSK said in its fourth quarter 2017 earnings report. “The group is cooperating and responding to these requests.”

The SFO inquiry followed investigations initiated by China’s Ministry of Public Security in June 2013, which resulted in a 2014 ruling, finding that GSK China...

Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.